Riskier Business: Atrial Fibrillation Stroke Prevention in the CHA
2
DS
2
-VASc Era
Circ Cardiovasc Qual Outcomes
.
2017 May;10(5):e003801.
doi: 10.1161/CIRCOUTCOMES.117.003801.
Authors
Thomas A Dewland
1
,
Eric C Stecker
2
Affiliations
1
From the Knight Cardiovascular Institute, Oregon Health & Science University, Portland.
2
From the Knight Cardiovascular Institute, Oregon Health & Science University, Portland. steckere@ohsu.edu.
PMID:
28506983
DOI:
10.1161/CIRCOUTCOMES.117.003801
No abstract available
Keywords:
Editorials; anticoagulants; atrial fibrillation; risk assessment; stroke.
Publication types
Editorial
Comment
MeSH terms
Anticoagulants*
Atrial Fibrillation*
Humans
Risk
Risk Assessment
Risk Factors
Stroke
Substances
Anticoagulants